📊 LGVN Key Takeaways
Is LGVN a Good Investment? Thesis Analysis
Longeveron is a pharmaceutical company in acute financial distress with collapsing revenue (-49.9% YoY), unsustainable operating losses of -$23.3M on only $1.2M revenue, and negative free cash flow of -$18.9M. With approximately $4.7M in cash and monthly burn rates implying ~3 months of runway, the company faces imminent liquidity crisis without significant capital infusion or dramatic burn reduction.
Why Buy LGVN? Key Strengths
- Gross margin of 67% demonstrates acceptable unit economics if revenue scale could be achieved
- Minimal debt burden with Debt/Equity of 0.03x reduces financial leverage risk
- Diluted EPS improved 50.8% YoY indicating partial stabilization of losses from prior year
LGVN Investment Risks to Consider
- Critical cash runway of approximately 3 months based on $4.7M cash against $18.6M annual operating burn rate
- Revenue collapse of 49.9% YoY signals severe loss of commercial traction or clinical setbacks
- Operating margin of -1942.2% and net margin of -1893.6% are completely unsustainable and indicate fundamental business model failure at current scale
- Negative free cash flow of -$18.9M with no path to positive cash generation visible in near term
- Pharmaceutical sector capital intensity requires sustained funding access that appears increasingly constrained
Key Metrics to Watch
- Monthly operating cash burn rate and quarterly cash position decline trajectory
- Revenue stabilization and any return to growth following 49.9% YoY decline
- Capital raise announcements, equity dilution, or strategic transaction necessity timeline
- Gross margin sustainability as company scales or pivots operations
LGVN Financial Metrics
💡 AI Analyst Insight
Longeveron Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
LGVN Profitability Ratios
LGVN vs Healthcare Sector
How Longeveron Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is LGVN Overvalued or Undervalued?
Based on fundamental analysis, Longeveron Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
LGVN Balance Sheet & Liquidity
LGVN 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Longeveron Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.62 indicates the company is currently unprofitable.
LGVN Growth Metrics (YoY)
LGVN Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $137.0K | -$4.4M | $-0.34 |
| Q2 2025 | $316.0K | -$3.4M | $-0.33 |
| Q1 2025 | $381.0K | -$4.1M | $-0.34 |
| Q3 2024 | $150.0K | -$4.4M | $-0.34 |
| Q2 2024 | $217.0K | -$3.4M | $-1.83 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
LGVN Capital Allocation
LGVN SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Longeveron Inc. (CIK: 0001721484)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LGVN
What is the AI rating for LGVN?
Longeveron Inc. (LGVN) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are LGVN's key strengths?
Claude: Gross margin of 67% demonstrates acceptable unit economics if revenue scale could be achieved. Minimal debt burden with Debt/Equity of 0.03x reduces financial leverage risk.
What are the risks of investing in LGVN?
Claude: Critical cash runway of approximately 3 months based on $4.7M cash against $18.6M annual operating burn rate. Revenue collapse of 49.9% YoY signals severe loss of commercial traction or clinical setbacks.
What is LGVN's revenue and growth?
Longeveron Inc. reported revenue of $1.2M.
Does LGVN pay dividends?
Longeveron Inc. does not currently pay dividends.
Where can I find LGVN SEC filings?
Official SEC filings for Longeveron Inc. (CIK: 0001721484) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LGVN's EPS?
Longeveron Inc. has a diluted EPS of $-1.29.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LGVN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Longeveron Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LGVN stock overvalued or undervalued?
Valuation metrics for LGVN: ROE of -400.1% (sector avg: 15%), net margin of -1,893.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LGVN stock in 2026?
Our dual AI analysis gives Longeveron Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LGVN's free cash flow?
Longeveron Inc.'s operating cash flow is $-18.6M, with capital expenditures of $245.0K. FCF margin is -1,575.5%.
How does LGVN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,893.6% (avg: 12%), ROE -400.1% (avg: 15%), current ratio 1.33 (avg: 2).